China investors step up focus on medtech, healthcare services
This article was originally published in Clinica
Executive Summary
Medical devices, clinical services and mHealth technology took a significant chunk of the near-$2m that went into healthcare-related investment in China last year, according to Zero2IPO, a local private equity fund. While pharmaceuticals still accounted for 46% of total M&A investment, medical devices came second with 33% and health services made up the remainder.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.